PacBio Integrates Long-Read Sequencing into Global Rare Disease Network
Event summary
- PacBio is partnering with iHope, a global rare disease genomics program, to integrate its HiFi long-read sequencing technology.
- iHope supports over 1,000 patients annually across 14 countries with a network of 25 clinical sites.
- The collaboration aims to expand genomic insights for rare disease diagnosis and potentially support precision therapeutic approaches.
- Integration of PacBio’s sequencing is expected to begin in early 2026.
The big picture
This partnership represents a strategic move for PacBio to expand its reach beyond research labs and into clinical diagnostics, a higher-margin segment of the genomics market. iHope’s global network provides PacBio with immediate access to a large patient population and a platform for demonstrating the clinical utility of long-read sequencing. The collaboration also highlights the increasing importance of multi-technology approaches in rare disease diagnosis, as short-read sequencing alone often fails to identify all relevant genetic variants.
What we're watching
- Clinical Adoption
- The speed and efficiency of HiFi sequencing integration across iHope’s 25 clinical sites will be a key indicator of PacBio’s ability to scale its technology into complex, distributed networks.
- Diagnostic Impact
- The actual improvement in diagnostic rates for previously undiagnosed rare disease patients, attributable to PacBio’s long-read sequencing, will be crucial to justifying the investment and expanding the partnership.
- Therapeutic Pipeline
- Whether the collaboration yields tangible progress in identifying targets for antisense oligonucleotide therapies will determine the long-term strategic value of this partnership for PacBio.
Related topics